CMV immunity and infection risk after stem cell transplant
Part of Blood & lymphatic, Immune system & allergy, Infections clinical trials.
This study looks at how well your immune system fights CMV (a common virus) after you stop taking a preventive medicine called Letermovir. It aims to see if your immune recovery can predict later CMV infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You had a positive CMV antibody test (showing past exposure) before your stem cell transplant.
- You received your first allogeneic (donor) stem cell transplant (from bone marrow, blood, or cord blood).
- You are currently within the first 28 days after your transplant.
- Your doctor plans to give you the CMV-prevention drug Letermovir, starting in the first 28 days after transplant and continuing until about 100 days after transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a blood test to measure your immune system's ability to fight CMV, a common virus after transplant. The results will help your doctors decide if you can safely stop taking the antiviral medication letermovir earlier to avoid unnecessary side effects.
This trial tests whether the drug letermovir can prevent cytomegalovirus (CMV) infection in people who have had a stem cell transplant. It is for adults who are CMV-positive and have not yet had a CMV infection.
This trial tests whether doctors can safely stop a CMV prevention medication (letermovir) earlier by using blood tests to check your immune system's strength. CMV is a virus that can become dangerous after stem cell transplant, and this study aims to prevent it while minimizing unnecessary medicine.
This trial tests whether taking letermovir for a longer time can prevent CMV (a common virus) from reactivating in adults with certain risk factors after a donor stem cell transplant. If you're preparing for your first transplant and have a high-risk donor or conditioning, this study may be an option.
This study tests if doctors can safely stop the anti-CMV drug letermovir earlier in stem cell transplant patients who have recovered their immune system. It focuses on patients who are at high risk for CMV but currently have no active infection.
This trial tests a treatment using specially grown immune cells (virus-specific lymphocytes) to fight a stubborn CMV infection that hasn't gotten better with usual medicines. It is for people who have had a stem cell transplant and need help controlling CMV.
Hear when a new Cytomegalovirus Cell Mediated Immunity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.